Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Ophthalmology. 2010 May;117(5):1013-23. doi: 10.1016/j.ophtha.2009.10.018. Epub 2010 Jan 25.
To identify the risk factors predictive of development of tumor-related lipid exudation (TRLE) after plaque radiotherapy of posterior uveal melanoma.
Case-control study.
Cases included 294 patients with posterior uveal melanoma who had developed TRLE after plaque radiotherapy. Controls included 294 patients with posterior uveal melanoma who had not developed TRLE after plaque radiotherapy. Controls were matched with cases for age, gender, and initial tumor thickness.
Data were extracted from medical charts containing demographic, clinical, and treatment information. Detailed fundus drawings and color fundus photographs were reviewed for each patient.
Tumor and ocular features of eyes with posterior uveal melanoma treated with plaque radiotherapy.
Multivariate analysis identified Bruch's membrane rupture (P<0.001), serous retinal detachment (RD) before radiation (P< or =0.019), closer proximity to the optic disc and foveola (P = 0.004 and 0.013, respectively), greater tumor base (P = 0.035), failure to receive transpupillary thermotherapy (TTT) after radiation (P<0.001), and initial increase of serous RD after radiation (P<0.001) as significant risk factors predictive of development of TRLE after plaque radiotherapy of posterior uveal melanoma. Radiation dose at the tumor base correlated with maximum extent of TRLE (P = 0.003). The mean interval between plaque radiotherapy and onset of TRLE was 14 months (median, 11 months; range, 2-97 months), with 88% of cases developing TRLE within 2 years of radiation. The interval between the onset of TRLE and the first evidence of its regression was a mean of 33 months (median, 38 months; range, 2-194 months).
Our study identified Bruch's membrane rupture as an important factor predisposing to development of TRLE after plaque radiotherapy of posterior uveal melanoma. Other predictive factors included serous RD before radiation, large tumor basal diameter, posterior tumor location, lack of adjunctive TTT, and early increase of serous RD after plaque radiotherapy.
确定预测眼后段黑色素瘤瘤灶放射性光凝治疗后肿瘤相关脂质渗出(TRLE)发生的风险因素。
病例对照研究。
病例组纳入 294 例眼后段黑色素瘤瘤灶放射性光凝治疗后发生 TRLE 的患者。对照组纳入 294 例眼后段黑色素瘤瘤灶放射性光凝治疗后未发生 TRLE 的患者。对照组与病例组在年龄、性别和初始肿瘤厚度上相匹配。
数据从包含人口统计学、临床和治疗信息的病历中提取。对每位患者的详细眼底图和眼底彩照进行了回顾。
接受瘤灶放射性光凝治疗的眼后段黑色素瘤患者的肿瘤和眼部特征。
多变量分析确定了脉络膜破裂(P<0.001)、放射性治疗前浆液性视网膜脱离(RD)(P<或=0.019)、靠近视盘和黄斑(P=0.004 和 0.013)、更大的肿瘤基底(P=0.035)、放射性治疗后未行透热疗法(TTT)(P<0.001)和放射性治疗后浆液性 RD 最初增加(P<0.001)为眼后段黑色素瘤瘤灶放射性光凝治疗后发生 TRLE 的显著预测因素。肿瘤基底的放射剂量与 TRLE 的最大程度相关(P=0.003)。瘤灶放射性光凝治疗与 TRLE 发病之间的平均间隔时间为 14 个月(中位数为 11 个月;范围为 2-97 个月),88%的病例在放射性治疗后 2 年内发生 TRLE。TRLE 发病与首次出现其消退之间的间隔时间平均为 33 个月(中位数为 38 个月;范围为 2-194 个月)。
本研究确定脉络膜破裂是眼后段黑色素瘤瘤灶放射性光凝治疗后发生 TRLE 的一个重要因素。其他预测因素包括放射性治疗前的浆液性 RD、大肿瘤基底直径、肿瘤后位、缺乏辅助性 TTT 和瘤灶放射性光凝治疗后浆液性 RD 的早期增加。